Medimaging Integrated Solution, an innovative smart medical technology company, announced that its revenue in December 2024 surged to NT$116 million, marking a record monthly high. This represents an over twofold increase compared to both the previous month and the same period last year, driving the company’s annual revenue to a new peak. Looking ahead to 2025, the company’s multiple growth engines are set to further boost its performance. These include the official Q1 shipment of its disposable cystoscope, licensed to Boston Scientific (NYSE: BSX); ongoing commercial contract discussions for its disposable bronchoscope with the largest emergency medical services company in the U.S.; and a newly signed distribution agreement for veterinary use with a renowned publicly listed Japanese medical device company. With these developments, the company anticipates strong double-digit growth in 2025.
Read more
